CrossRefPubMed 10. Li S, Takeuchi F, Wang J, et al. Mesenchymal-epithelial interactions
involving epiregulin in tuberous sclerosis complex hamaratomas. PNAS 2008; 105: 3539–44.CrossRefPubMed 11. Darling TN. Hamartomas and tubers from defects in harmartin-tuberin. J Am Acad Dermatol 2004; 51: S9–11.CrossRefPubMed 12. Bissler JJ, McCormack FX, Young LR, et al. Rapamycin for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Engl J Med see more 2008; 358: 140–51.CrossRefPubMed 13. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490–8.CrossRefPubMed 14. Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cells astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008; 23: 1238–9.CrossRefPubMed 15. Glasgow CG, Steagall WK, Taveira-DaSilva A, et al.
Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Resp Med selleck 2010; 104: S45–58.CrossRef 16. Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007; 57: 1046–50.CrossRefPubMed 17. Roach ES, DiMario FJ, Kandt RS, et al. Tuberous sclerosis consensus conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14: 401–7.CrossRefPubMed 18. Foster RS, Bint LJ, Halbert AR. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol 2012; 53: 52–6.CrossRef 19. Truchuelo T, Diaz-Ley B, Rios L, et al. Facial angiofibromas treated with topical SDHB rapamycin: an excellent choice with fast response. Dermatol Online J 2012; 18: 15.PubMed 20. Wataya-Kaneda M, Tanaka M, Nakamura A, et al. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Arch Dermatol 2012; 148: 138–9.CrossRefPubMed 21. DeKlotz CM, Ogram AE, Singh S, et al. Dramatic improvement
of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol 2011; 147: 1116–7.CrossRefPubMed 22. Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis-associated facial angiofibroma. J Eur Acad Dermatol Venereol. Epub 2011 Aug 11 23. Valeron-Almazan P, Vitiello M, Abuchar A, et al. Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis. Actas Dermosifiliogr 2012; 103: 165–6.CrossRefPubMed 24. Mutizwa MM, Berk DR, Anadkat MJ. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mg mL−1) in two patients with tuberous sclerosis. Br J Dermatol 2011; 165: 922–3.CrossRefPubMed 25. Wataya-Kaneda M, Tanaka M, Nakamura A, et al.